Chang Yu-Ying, Yen Chia-Jui, Chan Shih-Huang, Chou Yi-Wen, Lee Yun-Ping, Bao Ching-Yu, Huang Chien-Jung, Huang W

Idioma: Ingles.
Referencias bibliográficas: 38
Paginas: 843-456
Archivo PDF: 663.28 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.

2. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014; 28: 753-70.

3. Arbuthnot P, Kew M. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol 2001; 82: 77-100.

4. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona- 2000 EASL conference. European Association for the Study of the Liver. EASL Conference. J Hepatol 2001; 35: 421-30.

5. Zhu K, Dai Z, Zhou J. Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res 2013; 1: 10.

6. Hui AM, Makuuchi M, Li X. Cell cycle regulators and human hepatocarcinogenesis. Hepato Gastroenterology 1998; 45: 1635-42.

7. Ou Y, Rattner JB. The centrosome in higher organisms: structure, composition, and duplication. Int Rev Cytol 2004; 238: 119-82.

8. Wang Q, Hirohashi Y, Furuuchi K, Zhao H, Liu Q, Zhang H, Murali R, et al. The centrosome in normal and transformed cells. DNA Cell Biol 2004; 23: 475-89.

9. Fry AM, O’Regan L, Sabir SR, Bayliss R. Cell cycle regulation by the NEK family of protein kinases. J Cell Sci 2012; 125: 4423-33.

10. Hayward DG, Fry AM. Nek2 kinase in chromosome instability and cancer. Cancer Lett 2006; 237: 155-66.

11. Xia J, Franqui Machin R, Gu Z, Zhan F. Role of NEK2A in human cancer and its therapeutic potentials. BioMed Res Int 2015; 2015: 862461.

12. Wei R, Ngo B, Wu G, Lee WH. Phosphorylation of the Ndc80 complex protein, HEC1, by Nek2 kinase modulates chromosome alignment and signaling of the spindle assembly checkpoint. Mol Biol Cell 2011; 22: 3584-94.

13. Sonn S, Jeong Y, Rhee K. Nip2/centrobin may be a substrate of Nek2 that is required for proper spindle assembly during mitosis in early mouse embryos. Mol Reprod Dev 2009; 76: 587-92.

14. Liu Q, Hirohashi Y, Du X, Greene MI, Wang Q. Nek2 targets the mitotic checkpoint proteins Mad2 and Cdc20: a mechanism for aneuploidy in cancer. Exp Mol Pathol 2010; 88: 225-33.

15. Barbagallo F, Paronetto MP, Franco R, Chieffi P, Dolci S, Fry AM, Geremia R, et al. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas. J Pathol 2009; 217: 431-41.

16. Neal CP, Fry AM, Moreman C, McGregor A, Garcea G, Berry DP, Manson MM. Overexpression of the Nek2 kinase in colorectal cancer correlates with beta-catenin relocalization and shortened cancer-specific survival. J Surg Oncol 2014; 110: 828-38.

17. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006; 124: 1283-98.

18. Hsieh YH, Su IJ, Yen CJ, Tsai TF, Tsai HW, Tsai HN, Huang YJ, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients. Carcinogenesis 2013; 34: 475-85.

19. Das TK, Dana D, Paroly SS, Perumal SK, Singh S, Jhun H, Pendse J, et al. Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasis. Oncogenesis 2013; 2: e69.

20. Hsieh HC, Hsieh YH, Huang YH, Shen FC, Tsai HN, Tsai JH, Lai YT, et al. HHR23A, a human homolog of Saccharomyces cerevisiae Rad23, regulates xeroderma pigmentosum C protein and is required for nucleotide excision repair. Biochem Biophys Res Commun 2005; 335: 181-7.

21. Hsieh YH, Chang YY, Su IJ, Yen CJ, Liu YR, Liu RJ, Hsieh WC, et al. Hepatitis B virus pre-S2 mutant large surface protein inhibits DNA double-strand break repair and leads to genome instability in hepatocarcinogenesis. J Pathol 2015; 236: 337-47.

22. Hosmer DW, Lemeshow S. Applied Logistic Regression. 3rd ed. John Wiley & Sons, Inc; 2000.

23. Yen CJ, Ai YL, Tsai HW, Chan SH, Su IJ, Yen CS, Cheng YC, et al. Hepatitis B virus surface gene pr-S2 mutant as a highrisk serum marker for hepatoma recurrence after curative hepatic resection. Hepatology [In press] 2018.

24. Koff A, Polyak K. p27KIP1, an inhibitor of cyclin-dependent kinases. Prog Cell Cycle Res 1995; 1: 141-7.

25. Hsieh YH, Su IJ, Wang HC, Tsai JH, Huang YJ, Chang WW, Lai MD, et al. Hepatitis B virus pre-S2 mutant surface antigen induces degradation of cyclin-dependent kinase inhibitor p27Kip1 through c-Jun activation domain-binding protein 1. Mol Cancer Res 2007; 5: 1063-72.

26. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67.

27. Mardin BR, Agircan FG, Lange C, Schiebel E. Plk1 controls the Nek2A-PP1ã antagonism in centrosome disjunction. Curr Biol 2011; 21: 1145-51.

28. Mbom BC, Siemers KA, Ostrowski MA, Nelson WJ, Barth AI. Nek2 phosphorylates and stabilizes beta-catenin at mitotic centrosomes downstream of Plk1. Mol Biol Cell 2014; 25: 977-91.

29. Calvisi DF, Pinna F, Ladu S, Pellegrino R, Simile MM, Frau M, De Miglio MR, et al. Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut 2009; 58: 679-87.

30. Wonsey DR, Follettie MT. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 2005; 65: 5181-9.

31. Jiang L, Wang P, Chen L, Chen H. Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells. Int J Clin Exp Pathol 2014; 7: 5450-60.

32. Garofalo A, Sholl L, Reardon B, Taylor-Weiner A, Amin-Mansour A, Miao D, Liu D, et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med 2016; 8: 79.

33. Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol 2014; 7: 70.

34. Li G, Zhong Y, Shen Q, Zhou Y, Deng X, Li C, Chen J, et al. NEK2 serves as a prognostic biomarker for hepatocellular carcinoma. Int J Oncol 2017; 50: 405-13.

35. Wubetu GY, Morine Y, Teraoku H, Yoshikawa M, Ishikawa D, Yamada S, Ikemoto T, et al. High NEK2 expression is a predictor of tumor recurrence in hepatocellular carcinoma patients after hepatectomy. Anticancer Res 2016; 36: 757-62.

36. Wu SM, Lin SL, Lee KY, Chuang HC, Feng PH, Cheng WL, Liao CJ, et al. Hepatoma cell functions modulated by NEK2 are associated with liver cancerprogression. Int J Cancer 2017; 140: 1581-96.

37. Naro C, Barbagallo F, Chieffi P, Bourgeois CF, Paronetto MP, Sette C. The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival. Nucleic Acids Res 2014; 42: 3218-27.

38. Gu Z, Xia J, Xu HW, Frech I, Tricot G, Zhan FH. NEK2 promotes aerobic glycolysis in multiple myeloma through regulating splicing of pyruvate kinase. J Hematol Oncol 2017; 10: 17.